// App-Quantinova.ai

: Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.

Researchers

Presenter

  • Wang Yk

Principal Investigators

  • Jifang Gong

  • Yuping Sun

  • Jian Zhang

  • Shuqin Ni

  • Jie Hou

  • Xiaohua Chen

  • Yusheng Wang

  • Qin Yu

  • Xiangdong Qu

  • Yejie Du

  • Li Wei

  • Tao Yu

  • Lin Shen

Medical Centers

  • Phase I Center, ShanDong Cancer Hospital, Jinan, China

  • QureBio Ltd., Shanghai, China

  • Phase I Center, Peking University (PKU) Care, Luzhong Hospital, Zibo, China

  • Phase I Center, West China Second Hospital, Sichuan University, Chengdu, China

  • Phase I Center, ShanDong Cancer Hospital, Jinan, China

  • Department of breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

  • Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China

  • Department of Medical Oncology, Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China

  • Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, China

  • Department of Medical Oncology, Peking University (PKU) Care, Luzhong Hospital, Zibo, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Claudin 18.2

  • Programmed death-ligand 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Single Arm

  • Multicenteric

  • Expansion Study

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT04856150

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved